IPN Ipsen SA

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights

and shares composing the share capital

(in accordance with Article L.233-8 II of the French Commercial Code and

Article 223-16 of the General Regulation of the Autorité des Marchés Financiers)

Market: Euronext Paris

ISIN Code: FR 0010259150

LEI: 549300M6SGDPB4Z94P11

Date Total number of shares composing the share capital Total number of voting rights (1)
31 October 2024 83,814,526 Gross total* of voting rights: 132,135,791
Net total** of voting rights: 131,036,178

(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10).

* Gross total = total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The « Gross total » is used as a basis for the calculation of threshold crossings.

** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.

Attachment



EN
07/11/2024

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Bylvay® (odevixibat) data shows sustained improvement in severe itch a...

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label extension studies: late-breaking abstract (#5045) on PEDFIC 2 in Progressive Famili...

November 18, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Bylvay® (odévixibat) montre une amélioration soutenue en termes de sév...

Bylvay® (odévixibat) montre une amélioration soutenue en termes de sévérité des démangeaisons et de taux d’acides biliaires sériques chez les patients atteints de CIFP et du SAG Ipsen met en avant 3 nouvelles présentations ainsi que 8 abstracts dans le cadre de son portefeuille de maladies cholestatiques rares du foie au congrès 2024 de l’AASLD. PARIS, FRANCE, le 18 novembre 2024 Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd’hui la présentation de données lors du congrès de l’American Association for the Study of Liver Diseases (AASLD) évaluant l’efficacité et le prof...

November 18, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen - October 2024 - Monthly information relative to the total numbe...

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting righ...

November 7, 2024 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen - Octobre 2024 - Information mensuelle relative au nombre total ...

Ipsen - Octobre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Paris Code ISIN : FR 0010259150LEI : 549300M6SGDPB4Z94P11 Date Nombre total d’actions composant le capital socialNombre total de droits de vote (1)31 octobre 202483 814 526Total brut* des droit...

November 7, 2024 1 EN
Benoit Valleaux ... (+2)
  • Benoit Valleaux
  • Steven Gould
ACA CREDIT AGRICOLE...
INFINEON INFINEON TECHNO... ... (+25)

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/23/2024

Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the anti-C...

ACA CREDIT AGRICOLE SA
INFINEON INFINEON TECHNOLOGIES AG
HEIA HEINEKEN NV
AI AIR LIQUIDE SA
IPN IPSEN SA
DB1 DEUTSCHE BOERSE AG
BNP BNP PARIBAS SA CLASS A
LI KLEPIERRE SA
COV COVIVIO SA
ROG ROCHE HOLDING LTD
HO THALES SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
GLE SOCIETE GENERALE S.A. CLASS A
OR L'OREAL SA
BC8 BECHTLE AG
ELI ELIA GROUP SA/NV
ASSA B ASSA ABLOY AB CLASS B
ENG ENAGAS SA
IBE IBERDROLA SA
RIO RIO TINTO PLC
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
AKZA AKZO NOBEL N.V.
IHG INTERCONTINENTAL HOTELS GROUP PLC
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
10/23/24 October 23, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch